{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:49:10Z","timestamp":1790689750437,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007744","name":"Association pour le D\u00e9veloppement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014012","name":"FightMND","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejphar.2020.173446","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T02:28:16Z","timestamp":1596076096000},"page":"173446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases"],"prefix":"10.1016","volume":"884","author":[{"given":"Alexandra","family":"Bouscary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Quessada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Ren\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyuan","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173446_bib1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173446_bib2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbapap.2006.08.012","article-title":"Small molecule pharmacological chaperones: from thermodynamic stabilization to pharmaceutical drugs","volume":"1764","author":"Arakawa","year":"2006","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"key":"10.1016\/j.ejphar.2020.173446_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17389-9","article-title":"Lipidomics reveals cerebrospinal-fluid signatures of ALS","volume":"7","author":"Blasco","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.173446_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00883","article-title":"Ambroxol hydrochloride improves motor functions and extends survival in a mouse model of familial amyotrophic lateral sclerosis","volume":"10","author":"Bouscary","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173446_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nchembio0207-84","article-title":"Getting into the fold","volume":"3","author":"Brooks","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2020.173446_bib6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/jnc.14685","article-title":"GM1 promotes TrkA-mediated neuroblastoma cell differentiation by occupying a plasma membrane domain different from TrkA","volume":"149","author":"Chiricozzi","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2020.173446_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.10312","article-title":"Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress - induced death of motor neurons in amyotrophic lateral sclerosis","volume":"52","author":"Cutler","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2020.173446_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-642-45106-5_5","article-title":"Trk receptors","volume":"220","author":"Deinhardt","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173446_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcn\/74.3.328","article-title":"Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis","volume":"74","author":"Desport","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ejphar.2020.173446_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10719-020-09919-x","article-title":"Gangliosides in the differentiation process of primary neurons: the specific role of GM1-oligosaccharide","volume":"37","author":"Di Biase","year":"2020","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ejphar.2020.173446_bib11","doi-asserted-by":"crossref","first-page":"8100","DOI":"10.1073\/pnas.1508767112","article-title":"Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis","volume":"112","author":"Dodge","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2020.173446_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617734734","article-title":"Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis","volume":"11","author":"Dorst","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ejphar.2020.173446_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(10)70224-6","article-title":"Energy metabolism in amyotrophic lateral sclerosis","volume":"10","author":"Dupuis","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173446_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.173446_bib15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0024-3205(96)00431-6","article-title":"The antioxidative activity of the mucoregulatory agents: ambroxol, bromhexine and N-acetyl-L-cysteine. A pulse radiolysis study","volume":"59","author":"Felix","year":"1996","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2020.173446_bib16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.neuropharm.2005.08.004","article-title":"Ambroxol, a Nav1.8-preferring Na+ channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain","volume":"49","author":"Gaida","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2020.173446_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10875-014-0026-3","article-title":"MMN: from immunological cross-talk to conduction block","volume":"34","author":"Harschnitz","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejphar.2020.173446_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2017.00433","article-title":"Sphingolipid metabolism is dysregulated at transcriptomic and metabolic levels in the spinal cord of an animal model of amyotrophic lateral sclerosis","volume":"10","author":"Henriques","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173446_bib19","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1093\/hmg\/ddv439","article-title":"Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase","volume":"24","author":"Henriques","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2020.173446_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-05313-0","article-title":"Inhibition of \u03b2-glucocerebrosidase activity preserves motor unit integrity in a mouse model of amyotrophic lateral sclerosis","volume":"7","author":"Henriques","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.173446_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0773.2003.920407.x","article-title":"Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide","volume":"92","author":"Jang","year":"2003","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2020.173446_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ene.13468","article-title":"Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis","volume":"25","author":"J\u00e9sus","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2020.173446_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-8552-4_2","article-title":"Gangliosides of the nervous system","author":"Ledeen","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2020.173446_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1034\/j.1600-0773.2002.910309.x","article-title":"Ambroxol inhibits peroxynitrite-induced damage of \u03b11-antiproteinase and free radical production in activated phagocytic cells","volume":"91","author":"Lee","year":"2002","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2020.173446_bib25","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2020.173446_bib26","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2020.173446_bib27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","article-title":"Ambroxol in the 21st century: pharmacological and clinical update","volume":"4","author":"Malerba","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2020.173446_bib28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2020.173446_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13837","article-title":"Neurological effects of glucocerebrosidase gene mutations","volume":"26","author":"Mullin","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2020.173446_bib30","first-page":"1","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","author":"Mullin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejphar.2020.173446_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejphar.2020.173446_bib32","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170069","article-title":"Sphingolipids: membrane microdomains in brain development, function and neurological diseases","volume":"7","author":"Olsen","year":"2017","journal-title":"Open Biol"},{"key":"10.1016\/j.ejphar.2020.173446_bib33","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/sj.bjp.0705497","article-title":"In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism","volume":"140","author":"Ottonello","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173446_bib34","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2020.173446_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2017.00068","article-title":"ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?","volume":"9","author":"Petrov","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2020.173446_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/17482960902822960","article-title":"Impaired glucose tolerance in patients with amyotrophic lateral sclerosis","volume":"11","author":"Pradat","year":"2010","journal-title":"Amyotroph Lateral Scler."},{"key":"10.1016\/j.ejphar.2020.173446_bib37","first-page":"194","article-title":"Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat: clinical proof of concept","volume":"52","author":"Schutz","year":"2002","journal-title":"Arzneimittel-Forschung\/Drug Res."},{"key":"10.1016\/j.ejphar.2020.173446_bib38","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s00216-011-4671-6","article-title":"Inhibitor screening of pharmacological chaperones for lysosomal \u03b2-glucocerebrosidase by capillary electrophoresis","volume":"399","author":"Shanmuganathan","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejphar.2020.173446_bib39","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/jnnp-2017-317887","article-title":"Hypermetabolism in ALS is associated with greater functional decline and shorter survival","volume":"89","author":"Steyn","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2020.173446_bib40","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"van Es","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173446_bib41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1124\/mol.62.3.433","article-title":"Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na+ channels by the secretolytic ambroxol","volume":"62","author":"Weiser","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173446_bib42","first-page":"18744","article-title":"Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers","volume":"8","author":"Yang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ejphar.2020.173446_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol. Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920305380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920305380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:09:30Z","timestamp":1762142970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920305380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":43,"alternative-id":["S0014299920305380"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173446","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"173446"}}